Medpace Holdings, Inc. $MEDP Position Increased by Sanctuary Advisors LLC

Sanctuary Advisors LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 63.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 3,504 shares of the company’s stock after buying an additional 1,358 shares during the quarter. Sanctuary Advisors LLC’s holdings in Medpace were worth $1,968,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Baillie Gifford & Co. raised its holdings in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price objective for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Robert W. Baird cut their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus target price of $467.08.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Bares Capital trims its stake in Medpace, a portfolio move that may reflect manager rebalancing or concern about near-term risks. Bares Capital Trims Stake
• Negative Sentiment: A class action has been filed against Medpace and certain officers alleging violations of the federal securities laws for the period Apr 22, 2025–Feb 9, 2026; this formal filing increases legal exposure and investor uncertainty. Bronstein, Gewirtz & Grossman Class Action
• Negative Sentiment: Multiple plaintiff firms are actively soliciting lead plaintiffs and issuing investor alerts (Schall, Gross, BFA Law, Pomerantz, Rosen, Faruqi & Faruqi, Portnoy, Robbins, SueWallSt, Frank R. Cruz, Robbins LLP). The flurry of filings/solicitations heightens the probability of consolidated litigation, potential discovery, legal fees and settlement risk. Examples: Schall Law Firm Gross Law Firm BFA Law Pomerantz
• Negative Sentiment: Media coverage highlights that peers (Agios) posted strong results while reporting noted Medpace flagged rising cancellations—this operational disclosure appears to be the proximate cause of the stock weakness and underpins many litigation claims alleging the company misrepresented backlog/cancellation risks. Agios / Medpace Cancellations Coverage

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 20.50% of the stock is owned by insiders.

Medpace Price Performance

Medpace stock opened at $417.54 on Monday. The company has a market capitalization of $11.92 billion, a price-to-earnings ratio of 26.24, a PEG ratio of 2.12 and a beta of 1.19. Medpace Holdings, Inc. has a one year low of $284.10 and a one year high of $628.92. The company’s fifty day moving average price is $468.91 and its two-hundred day moving average price is $532.96.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.